Tilray Brands, Inc. (2HQ.DE)
EUR 1.16
(0.43%)
EUR 1.16
(0.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 235.58 Million USD | 60.3% |
| 2022 | 146.96 Million USD | 25.8% |
| 2021 | 116.81 Million USD | -5.17% |
| 2020 | 123.18 Million USD | -10.53% |
| 2019 | 137.68 Million CAD | 146.99% |
| 2018 | 55.74 Million CAD | 75.8% |
| 2017 | 31.7 Million CAD | 146.95% |
| 2016 | 12.83 Million CAD | 180.16% |
| 2015 | 4.58 Million CAD | 616.58% |
| 2014 | 639.56 Thousand CAD | 262.38% |
| 2013 | -393.87 Thousand USD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 59.7 Million USD | -34.2% |
| 2023 Q1 | 44.19 Million USD | -34.2% |
| 2023 Q4 | 82.52 Million USD | 67.07% |
| 2023 Q3 | 49.39 Million USD | 4.19% |
| 2023 FY | 235.58 Million USD | 60.3% |
| 2023 Q2 | 47.4 Million USD | 7.27% |
| 2022 Q4 | 67.16 Million USD | 674.09% |
| 2022 FY | 146.96 Million USD | 25.8% |
| 2022 Q3 | -11.69 Million USD | -129.16% |
| 2022 Q2 | 40.12 Million USD | -17.46% |
| 2022 Q1 | 48.61 Million USD | 822.03% |
| 2021 FY | 116.81 Million USD | -5.17% |
| 2021 Q4 | -6.73 Million USD | -116.9% |
| 2021 Q1 | 50.95 Million USD | 126.49% |
| 2021 Q3 | 39.82 Million USD | 21.56% |
| 2021 Q2 | 32.76 Million USD | -35.7% |
| 2020 Q3 | 24.86 Million CAD | -18.23% |
| 2020 Q2 | 30.41 Million USD | -46.43% |
| 2020 FY | 123.18 Million USD | -10.53% |
| 2020 Q4 | 22.49 Million USD | -9.53% |
| 2020 Q1 | 56.77 Million USD | 66.19% |
| 2019 Q2 | 29.45 Million USD | -13.34% |
| 2019 Q3 | 44.05 Million USD | 49.59% |
| 2019 Q4 | 34.16 Million USD | -22.45% |
| 2019 FY | 137.68 Million CAD | 146.99% |
| 2019 Q1 | 33.98 Million USD | 23.28% |
| 2018 Q1 | 10.59 Million USD | -24.08% |
| 2018 FY | 55.74 Million CAD | 75.8% |
| 2018 Q4 | 27.56 Million USD | 109.55% |
| 2018 Q3 | 13.15 Million USD | 191.95% |
| 2018 Q2 | 4.5 Million USD | -57.48% |
| 2017 Q4 | 13.95 Million USD | 108.07% |
| 2017 FY | 31.7 Million CAD | 146.95% |
| 2017 Q3 | 6.7 Million USD | 39.2% |
| 2017 Q1 | 6.26 Million USD | 51.13% |
| 2017 Q2 | 4.81 Million USD | -23.04% |
| 2016 FY | 12.83 Million CAD | 180.16% |
| 2016 Q4 | 4.14 Million USD | 53.18% |
| 2016 Q1 | 2.88 Million CAD | 67.35% |
| 2016 Q3 | 2.7 Million USD | -11.81% |
| 2016 Q2 | 3.06 Million CAD | 6.16% |
| 2015 Q1 | 512.43 Thousand CAD | 8.47% |
| 2015 Q3 | 1.38 Million CAD | 41.93% |
| 2015 Q4 | 1.72 Million CAD | 24.23% |
| 2015 FY | 4.58 Million CAD | 616.58% |
| 2015 Q2 | 979.16 Thousand CAD | 91.08% |
| 2014 Q4 | 472.41 Thousand CAD | 129.66% |
| 2014 Q3 | 205.69 Thousand CAD | 6.73% |
| 2014 Q2 | 192.72 Thousand CAD | 211.55% |
| 2014 Q1 | -172.76 Thousand CAD | 2.08% |
| 2014 FY | 639.56 Thousand CAD | 262.38% |
| 2013 Q3 | -77.1 Thousand CAD | -18.99% |
| 2013 Q4 | -176.43 Thousand CAD | -128.83% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | -393.87 Thousand USD | 0.0% |
| 2013 Q2 | -64.8 Thousand CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| MPH Health Care AG | 180.33 Million EUR | -30.638% |
| Apontis Pharma AG | -3.33 Million EUR | 7161.347% |
| Dermapharm Holding SE | 342.86 Million EUR | 31.29% |
| Evotec SE | 175.05 Million EUR | -34.578% |
| MERCK Kommanditgesellschaft auf Aktien | 11.66 Billion EUR | 97.981% |
| PharmaSGP Holding SE | 91.63 Million EUR | -157.081% |
| SynBiotic SE | 1.5 Million EUR | -15538.488% |